Please assess the completion status of the following clinical trial:

Trial Title: Initial Treatment of Patients With Immune Thrombocytopenic Purpura

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must meet criteria for a diagnosis of ITP as specified by ASH guidelines~* Must be within 30 days after diagnosis of ITP at the time of randomization (diagnosis of ITP starts with first platelet count ≤ 100,000/μl)~* Platelet count ≤ 30,000/μl at the time ITP is diagnosed, and/or at some time between the diagnosis of ITP and study entry~* Platelet count ≤ 150,000/μl at the time of randomization~* Age ≥ 15 years~* If bone marrow examination is available, it must be compatible with ITP~* Subjects, or their legal guardians, must have the ability to provide informed consent~Exclusion Criteria:~* Rituximab therapy or splenectomy for ITP or for any other cause within the previous 8 weeks.~* Known HIV infection~* Known HCV infection~* Known systemic lupus erythematosus~* Pregnancy or breastfeeding~* Insulin-requiring diabetes mellitus~* Previous exposure to prednisone for ITP at a dose ≥ 1.5 mg/kg prednisone/day for ≥ 1 week prior to study entry~* Ongoing use of treatments that are known to inhibit platelet function, e.g. aspirin~* Anything that in the opinion of the investigator is likely to interfere with participation in the study~* Persons previously randomized in the ITP\^2 study~* Persons currently enrolled in other interventional clinical trials~* Exposure to thrombopoietic agent prior to study entry~* Previous exposure to dexamethasone for the treatment of ITP at a dose of 30 mg/day or greater for subjects \< 60 kg or 40 mg/day or greater for subjects \>= 60 kg for at least four days

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- High dose pulse dexamethasone (Type: EXPERIMENTAL): None
- Standard prednisone therapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).